# Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy

> **NCT02414100** · — · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University**

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Stage IA Pancreatic Cancer
- Stage IB Pancreatic Cancer
- Stage IIA Pancreatic Cancer
- Stage IIB Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Cytology Specimen Collection Procedure

## Key facts

- **NCT ID:** NCT02414100
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-12-12
- **Primary completion:** 2016-12-15
- **Final completion:** 2016-12-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No subjects were enrolled. Study team was not able to grow cell lines for the tumors.
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02414100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02414100, "Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02414100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*